Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Non Operating Investment Income: 2017-2025

Historic Non Operating Investment Income for Ligand Pharmaceuticals (LGND) over the last 9 years, with Sep 2025 value amounting to $7.8 million.

  • Ligand Pharmaceuticals' Non Operating Investment Income rose 223.97% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.5 million, marking a year-over-year decrease of 123.95%. This contributed to the annual value of $75.0 million for FY2024, which is 61.81% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Non Operating Investment Income of $7.8 million as of Q3 2025, which was up 730.46% from $939,000 recorded in Q2 2025.
  • Ligand Pharmaceuticals' Non Operating Investment Income's 5-year high stood at $110.8 million during Q1 2024, with a 5-year trough of -$23.9 million in Q4 2024.
  • For the 3-year period, Ligand Pharmaceuticals' Non Operating Investment Income averaged around $10.7 million, with its median value being $2.4 million (2024).
  • In the last 5 years, Ligand Pharmaceuticals' Non Operating Investment Income slumped by 6,480.00% in 2021 and then soared by 430.27% in 2022.
  • Quarterly analysis of 5 years shows Ligand Pharmaceuticals' Non Operating Investment Income stood at -$13.4 million in 2021, then surged by 430.27% to $44.2 million in 2022, then tumbled by 63.78% to $16.0 million in 2023, then plummeted by 249.14% to -$23.9 million in 2024, then surged by 223.97% to $7.8 million in 2025.
  • Its last three reported values are $7.8 million in Q3 2025, $939,000 for Q2 2025, and -$12.4 million during Q1 2025.